Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.

@article{Stefano2010RapidBO,
  title={Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.},
  author={Nicola De Stefano and François Curtin and Bettina Stubinski and Gregg Blevins and Jelena S. Drulovi{\'c} and Delphine Issard and Penko M Shotekov and Claudio Gasperini},
  journal={Multiple sclerosis},
  year={2010},
  volume={16 7},
  pages={888-92}
}
This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-beta1a in relapsing-remitting multiple sclerosis (RRMS). Patients (n = 180) were randomized (2 : 1) to IFN-beta1a or placebo for 16 weeks; all patients then received IFN-beta1a for 24 weeks. Monthly brain MRI was performed. At week 16, the mean number of combined unique active (CUA) lesions was lower with IFN-beta1a than with placebo (p < 0.001; 69% fewer lesions). The mean cumulative number of CUA… CONTINUE READING

From This Paper

Topics from this paper.
12 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…